Welcome to our dedicated page for Restart Life news (Ticker: NMLSF), a resource for investors and traders seeking the latest updates and insights on Restart Life stock.
Restart Life Sciences Corp. reports developments in its better-for-you functional food and consumer packaged goods portfolio. The company operates through Holy Crap Foods Inc., a wholly owned subsidiary focused on superseed cereals, oatmeal and related gut-health products, and also references wellness product lines such as BrainQ™ and BrainBalls™ for cognitive health.
Recurring updates cover Holy Crap Foods integration, wholesale and e-commerce sales channels, Amazon Canada and Walmart.ca distribution, certified manufacturing capabilities, product development with the University of Manitoba’s Richardson Centre for Food Technology and Research, and internal infrastructure for brand scaling. Company news also includes board appointments, capital-markets oversight, related-party share issuance disclosures and broader operational execution across its functional wellness platform.
Restart Life Sciences (OTC Pink: NMLSF) announced on December 17, 2025 that it will allocate capital to support newly planned food-related research initiatives aimed at its consumer health portfolio.
The company said it will narrow preferred research partners, pursue studies on ingredient quality, formulation performance, stability, sensory attributes and preliminary bioavailability, and expects findings to inform product refinement for brands such as BrainQ and BrainBalls. Additional updates will follow as research parameters and partnerships are defined.
Restart Life Sciences (OTC Pink: NMLSF) closed the first tranche of a non-brokered private placement on December 5, 2025, raising CDN$500,000 by issuing 5,000,000 units at CDN$0.10 per unit. Each unit includes one common share and one one-year warrant exercisable at CAD$0.10. The company paid CAD$16,800 in cash finder's fees and issued 60,000 non-transferable finder warrants exercisable at CAD$0.10 for one year. Proceeds are intended for health food trials, potential acquisitions, and general working capital. All securities are subject to a hold period ending April 6, 2026.
Nova Mentis Life Science Corp. (NMLSF) has entered into an intellectual property conveyance agreement with Ludwig Enterprises Inc. and Dr. Marvin S. Hausman. NOVA will assign its mRNA Neuro Panel and Serotonin Assay intellectual property to Ludwig. In exchange, Hausman will forgive NOVA's $245,712 debt, and Ludwig will issue 750,000 restricted common shares to NOVA. Additionally, NOVA will receive a 10-year royalty of 2.5% on revenue up to $245,712 and 5% thereafter from the Property's commercialization.
NOVA's Health Canada Phase 2a clinical trial for Fragile X Syndrome has faced recruitment challenges, with no candidates meeting enrollment requirements. The company's Board is actively seeking new business opportunities in the Life Sciences sector to create shareholder value.
Summary not available.
Summary not available.
Summary not available.
Wellbeing Digital Sciences Inc. (OTC: KONEF) announces the recruitment of participants for a pioneering clinical trial examining the effects of psilocybin on adults with fragile X syndrome (FXS). Conducted by its subsidiary KGK Sciences, the 28-day Phase IIA study is the first authorized by Health Canada allowing take-home psilocybin dosing. The study, set to treat its first participant in Q2 2023, aims to evaluate the safety and efficacy of Nova Mentis’ psilocybin drug (NM-1001) in a controlled environment, using advanced diagnostic technologies. Preliminary results are expected later this year, highlighting significant potential for psilocybin therapy in addressing unmet medical needs related to FXS.
Wellbeing Digital Sciences Inc. (KONEF, NMLSF) has announced that its subsidiary, KGK Sciences Inc., gained IRB approval in Canada to conduct a groundbreaking Phase IIA clinical trial. This study will test the efficacy of psilocybin on adults with fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (ASD). The trial is part of a partnership with Nova Mentis Life Science Corp., aiming to assess psilocybin's impact on cognitive and behavioral symptoms. Patient recruitment is expected to begin this year. Notably, Health Canada has granted special permission for participants to take the drug home, marking a significant milestone in clinical research. This trial supports Nova's ongoing efforts to improve treatment options for FXS patients, following their FDA Orphan Drug designation received in 2021.